Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13354032 | 0.84 | CES2 (0.46) | LMNAHTTTSHRMAPTL3MBTL1 | |
| SCHEMBL8403465 | 0.84 | LMNA (0.55) | LMNAMAPK1HTTRAB9ATSHR | |
| SCHEMBL21383062 | 0.81 | TSHR (0.55) | MAPK1TSHRTP53KDM4EGAA | |
| SCHEMBL27151 | 0.79 | CES2 (0.70) | LMNAMAPK1HTTRAB9ATSHR | |
| SCHEMBL29349680 | 0.79 | CES2 (0.70) | LMNAMAPK1HTTRAB9ATSHR | |
| SCHEMBL28368751 | 0.78 | LTA4H (0.50) | LMNAMAPK1RAB9ATSHRTP53 | |
| Hydrochloric Acid SCHEMBL31439055 | 0.77 | CES2 (0.67) | LMNAMAPK1HTTRAB9ATSHR | |
| Hydrochloric Acid SCHEMBL10557218 | 0.77 | CES2 (0.67) | LMNAMAPK1HTTRAB9ATSHR | |
| Hydrochloric Acid SCHEMBL31439035 | 0.77 | CES2 (0.67) | LMNAMAPK1HTTRAB9ATSHR | |
| SCHEMBL22926190 | 0.76 | HDAC6 (0.47) | HTTTSHRGAACA2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3859804-B1 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS | CANON KK (JP) | 2024-08-07 | — | — | EP | claimed |
| US-12245446-B2 | Semiconductor device having quantum dots, display device, imaging system, and moving body | CANON KABUSHIKI KAISHA (JP) | 2025-03-04 | — | — | US | disclosed |
| EP-3859804-B1 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS | CANON KK (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-113285024-A | Semiconductor device having quantum dots, display device, imaging system, and moving object | 佳能株式会社 | 2021-08-20 | — | — | CN | disclosed |
| US-20210242416-A1 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS, DISPLAY DEVICE, IMAGING SYSTEM, AND MOVING BODY | CANON KABUSHIKI KAISHA (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-3859804-A2 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS | CANON KABUSHIKI KAISHA (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-9597332-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597332-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597332-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016089990-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20110230403-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| EP-2342187-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010031813-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
| US-20110230403-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, HSD17B14 | LMNA 2362/4885MAPK1 1587/4885HTT 2300/4885 |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.